Untargeted metabolomics analysis of metabolite changes in gastric cancer patients from plateau regions.

Background: Metabolomics sequencing technology was used to investigate the changes of intestinal flora and metabolites in gastric cancer patients in plateau areas.

Aim: To investigate changes in gut microbiota and their metabolites in patients with gastric cancer from plateau regions using untargeted metabolomic sequencing.

Methods: Fresh morning fecal samples were collected from 30 gastric cancer patients diagnosed at a tertiary hospital in Qinghai Province and 30 healthy individuals (controls). Liquid chromatography-tandem mass spectrometry based untargeted metabolomic sequencing was used to analyze metabolite changes and predict metabolic function.

Results: Metabolomic analysis identified 281 metabolites in samples from both groups. These metabolites were categorized into eight major classes, listed in descending order of abundance: Lipids and lipid-like molecules (35.443%); organic acids and derivatives (29.114%); organic oxygen compounds (15.19%); nucleosides, nucleotides, and analogs (13.924%); organoheterocyclic compounds (2.532%), amino acids and peptides (1.266%); benzenoids (1.266%); and fatty acids (1.266%). Compared with the control group, the top 10 metabolites elevated in the gastric cancer group included: Dethiobiotin, glycylproline, glycine, hydroxyisocaproic acid, tyramine, methionine sulfoxide, 5-aminopentanoic acid, citrulline, betonicine, and formiminoglutamic acid and the top 10 decreased were: Cytidine, 5'-methylthioadenosine, trehalose, melibiose, lotaustralin, adenosine, inosine, ribothymidine, raffinose, and galactinol. Functional prediction analysis revealed that these differential metabolites were primarily enriched in 12 metabolic pathways, including purine metabolism, cysteine and methionine metabolism, galactose metabolism, lysine degradation, glycine, serine, and threonine metabolism, biotin metabolism, pyrimidine metabolism, arginine and proline metabolism, histidine metabolism, primary bile acid biosynthesis, starch and sucrose metabolism, and tyrosine metabolism.

Conclusion: Significant differences in intestinal microbial metabolites and associated metabolic pathways were observed between gastric cancer patients and healthy controls residing in plateau regions.